The estimated Net Worth of June Sherie Almenoff is at least $39.8 Thousand dollars as of 4 January 2019. June Almenoff owns over 1,475 units of Brainstorm Cell Therapeutics stock worth over $2,009 and over the last 10 years he sold BCLI stock worth over $0. In addition, he makes $37,780 as Independent Director at Brainstorm Cell Therapeutics.
Sign up
June Almenoff BCLI stock SEC Form 4 insiders trading
June has made over 7 trades of the Brainstorm Cell Therapeutics stock since 2014, according to the Form 4 filled with the SEC. Most recently he bought 1,475 units of BCLI stock worth $5,000 on 4 January 2019.
The largest trade he's ever made was buying 6,000 units of Brainstorm Cell Therapeutics stock on 6 February 2015 worth over $40,500. On average, June trades about 1,246 units every 102 days since 2014. As of 4 January 2019 he still owns at least 7,175 units of Brainstorm Cell Therapeutics stock.
You can see the complete history of June Almenoff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
June Almenoff biography
Dr. June S. Almenoff M.D., Ph.D. serves as Independent Director of the Company. Dr. June Almenoff is an accomplished executive with over 20 years of experience in the pharmaceutical industry. She is Chief Scientific Officer of RedHill Biopharma since May 2019 (consultant). She has broad therapeutic development and strategic experience including gastroenterology, rare disease, immune-inflammation, infectious diseases, CNS. She served as President and CMO of Furiex Pharmaceuticals (from 2010 to 2014). During her 4-year tenure, the company’s valuation increased ~10-fold, culminating in its acquisition by Actavis plc for ~$1.2B in 2014. Furiex’s lead product, eluxadoline (Viberzi TM), a novel gastrointestinal drug, is approved and marketed in US and EU. Prior to joining Furiex, Dr. Almenoff was at GlaxoSmithKline (GSK) from 1997 to 2010, where she held various positions of increasing responsibility in the R&D organization. During her 12 years at GSK, she was a Vice President in the Clinical Safety organization, chaired a PhRMA-FDA working group and worked in the area of scientific licensing. Dr. Almenoff also led the development of pioneering systems for minimizing risk in drug development which have been widely adapted by industry and regulators. Dr. Almenoff also served as CMO and COO of Innovate Biopharmaceuticals (2018). She has served as Executive Chair of RDD Pharma, a private, GI clinical stage biopharma company (2015-18 and BoD member 2018-2019) where she helped the company secure Series B as well as US Govt. Dept of Defense funding and currently serves as an independent director (since 2015). She was a Director of Tigenix NV (Nasdaq: TIG) from 2016 to 2018, until its acquisition for ~$600M. Dr. Almenoff served on the Board of Ohr Pharmaceutical (Nasdaq: OHRP-now NBSE) from 2013 to 2019, and serves on the investment advisory board of the Harrington Discovery Institute, a venture philanthropy. Dr. Almenoff received her B.A. cum laude from Smith College and graduated with AOA honors from the M.D.-Ph.D. prog
What is the salary of June Almenoff?
As the Independent Director of Brainstorm Cell Therapeutics, the total compensation of June Almenoff at Brainstorm Cell Therapeutics is $37,780. There are 9 executives at Brainstorm Cell Therapeutics getting paid more, with Chaim Lebovits having the highest compensation of $1,639,680.
How old is June Almenoff?
June Almenoff is 63, he's been the Independent Director of Brainstorm Cell Therapeutics since 2017. There are 1 older and 16 younger executives at Brainstorm Cell Therapeutics. The oldest executive at Brainstorm Cell Therapeutics, Inc. is Malcolm Taub, 74, who is the Independent Director.
What's June Almenoff's mailing address?
June's mailing address filed with the SEC is ONE COPLEY PARKWAY, SUITE 490, , MORRISVILLE, NC, 27560.
Insiders trading at Brainstorm Cell Therapeutics
Over the last 21 years, insiders at Brainstorm Cell Therapeutics have traded over $1,899,994 worth of Brainstorm Cell Therapeutics stock and bought 1,713,254 units worth $1,535,874 . The most active insiders traders include Corp. Accbt, Mike Frankenberger, and International Holdings Ltd..... On average, Brainstorm Cell Therapeutics executives and independent directors trade stock every 145 days with the average trade being worth of $206,459. The most recent stock trade was executed by Ibrahim B. Dagher on 19 July 2024, trading 63,000 units of BCLI stock currently worth $22,050.
What does Brainstorm Cell Therapeutics do?
brainstorm cell therapeutics inc. (nasdaq:bcli), is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative disorders such as als (lou gehrig's disease), multiple sclerosis (ms) and parkinson’s disease (pd). these diseases have limited treatment options and as such represent unmet medical needs. nurown™ is brainstorm’s proprietary process for the propagation and differentiation of adult, autologous mesenchymal stem cells (msc) into neurotrophic factor (ntf)-secreting cells, and the transplantation of these specialized cells at or near the affected tissue site. our platform technology essentially converts mscs into living drug delivery system for ntfs. we have obtained proof-of-concept in a variety of animal models of neurodegenerative diseases, including parkinson's, huntington's, als, ms, and peripheral nerve injury. we have completed two single-arm clinical trials in als patients, conducted in israel, which have demonstr
What does Brainstorm Cell Therapeutics's logo look like?
Complete history of June Almenoff stock trades at Brainstorm Cell Therapeutics and Tenax Therapeutics Inc
Brainstorm Cell Therapeutics executives and stock owners
Brainstorm Cell Therapeutics executives and other stock owners filed with the SEC include:
-
Chaim Lebovits,
Chief Exec. Officer -
Chaim Lebovits,
Chief Executive Officer -
Ralph Kern,
President, Chief Medical Officer -
Dr. Ralph Z. Kern,
Pres & Chief Medical Officer -
Dr. Stacy R. Lindborg Ph.D.,
Exec. VP & Chief Devel. Officer -
Preetam Shah,
Chief Financial Officer, Executive Vice President, Treasurer -
Irit Arbel,
Vice Chairman of the Board -
Malcolm Taub,
Independent Director -
Uri Yablonka,
Executive Vice President, Chief Business Officer, Director -
June Almenoff,
Independent Director -
Anthony Polverino,
Independent Director -
Arturo Araya,
Chief Commercial Officer -
Uri Yablonka,
Exec. VP, Chief Bus. Officer, Sec. & Director -
Dr. Irit Arbel DSc, Ph.D.,
Co-Founder & Independent Vice Chair of the Board -
Dr. Irit Arbel Ph.D., DSc,
Co-Founder & Independent Vice Chair of the Board -
Sankesh Abbhi,
Director -
Anthony Waclawski,
Executive Vice President - Global Head of Regulatory Affairs -
Stacy Lindborg,
Executive Vice President Head of Global Clinical Research -
David Setboun,
Chief Operating Officer, Executive Vice President -
Jacob Frenkel,
Chairman of the Board -
Antal Pearl-Lendner,
VP & Chief Legal Counsel -
Alla Patlis CPA, M.B.A.,
Controller & Interim CFO -
William K. White,
Sr. VP & Head of Market Access and Pricing -
Dr. Daniel Offen,
Chief Scientific Advisor -
Dr. Yael Gothelf,
VP of Scientific & Regulatory Affairs -
Dr. David Setboun M.B.A., Pharm.D.,
Exec. VP & COO -
Dr. Preetam Shah M.B.A., Ph.D.,
Exec. VP, CFO & Treasurer -
Mordechai Friedman,
Director -
International Holdings Ltd....,
-
Alon Pinkas,
Director -
Robert G L Shorr,
Director -
Yoram Bibring,
Chief Financial Officer -
Chen Schor,
Director -
Eyal Rubin,
CFO and Treasurer -
Nir Naor,
Director -
Alla Patlis,
See Remarks -
Anthony S. Fiorino,
Chief Executive Officer -
Liat Sossover,
Chief Financial Officer -
Avi Israeli,
Director -
Adrian Harel,
Acting Chief Executive Officer -
Corp. Accbt,
10% owner -
Aviv University Economic Co...,
10% owner -
Aviv University Tel,
10% owner -
Abraham Efrati,
Chief Executive Officer -
David Stolick,
Chief Financial Officer -
At Tel Aviv University Ltd ...,
10% owner -
Jonathan C Javitt,
Director -
Beck Yaffa,
President and CEO -
Moshe Lion,
Director -
Michael D Greenfield,
Director -
Yoram Drucker,
Chief Operating Officer -
Mike Frankenberger,
-
Kirk Taylor,
Chief Medical Officer -
Hartoun Hartounian,
EVP, Chief Operating Officer -
Ibrahim B. Dagher,
Chief Medical Officer